Work

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply

Year: 2023

Type: letter

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(22)00740-9

Authors: Thomas Powles, Joseph E Burgents, Lei Xu, Toni K Choueiri

Institutions: St Bartholomew's Hospital, Queen Mary University of London, Barts Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4313452525

Cites: 4

Cited by: 2

Related to: 10